Table 1_Upfront triple combination therapy with selexipag: insights from a real world coho

A retrospective study of 153 patients from Qilu Hospital of Shandong University between February 2022 and November 2023. The dataset likely contains clinical parameters for evaluating the safety and efficacy of selexipag-based triple therapy in Chinese patients with pulmonary arterial hypertension. It was authored by Xiaopei Cui and last updated on 2026-05-21.

Use Cases

• Compare initial versus sequential triple therapy outcomes based on hazard ratios for disease progression.
• Analyze changes in non-invasive risk stratification based on the French pulmonary hypertension network criteria.
• Model improvements in exercise capacity based on 6-minute walk distance (6MWD) data.
• Assess right heart remodeling based on echocardiogram parameters like right atrial area and tricuspid annular plane systolic excursion.

Strengths

• Includes data for 153 patients in safety analysis and 146 in efficacy analysis.
• Reports specific clinical outcomes, including a hazard ratio of 0.177 for disease progression.
• Contains a median follow-up period of 29 weeks and an average follow-up of 33 months.
• Uses a clear, single-center retrospective study design from a specific hospital.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• Data may reflect geographic and institutional bias inherent to a single-center study in China.

Provenance

Source

Qilu Hospital of Shandong University

Collection Method

Single-center, retrospective study.

Time Range

February 2022 to November 2023 (patient presentation), with follow-up data.

Freshness

Last updated 2026-05-21 05:44:06; freshness should be verified.

Geography

China (specifically, patients presenting to a hospital in Shandong province).